Pull to refresh
Logo
Daily Brief
Following
Why Ranks Sign Up
Zydus buys its way into U.S. specialty drugs

Zydus buys its way into U.S. specialty drugs

Money Moves

The Indian drugmaker closes its takeover of Assertio Holdings, winning a cancer-care drug after a three-way bidding contest.

Today: Zydus completes the takeover

Overview

Zydus, one of India's largest drugmakers, now owns a U.S. cancer-care drug. On June 16, 2026, it finished buying Assertio Holdings for $23.50 a share in cash, a deal worth about $166 million.

The purchase caps a year in which Zydus spent heavily to move from low-margin generics into branded U.S. medicines. It won Assertio only after topping two rival offers, a sign of how hard Indian firms are now pushing to own American drug brands.

Why it matters

An Indian generics maker now controls a U.S. cancer-support drug, part of a wave deciding who owns America's specialty medicines.

Questions about this story

No questions yet — be the first to ask.

Key Indicators

$166M
Deal value
Total cash Zydus paid for all Assertio shares.
$23.50
Price per share
The all-cash offer Assertio shareholders accepted.
7.8%
Premium over rival bid
How much Zydus topped Garda Therapeutics' $21.80 offer.
4
Acquisitions in a year
Deals Zydus struck across MedTech, biologics, and specialty drugs.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 3 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Higher or Lower Two numbers from this story. Guess which is bigger. 5 rounds to set a streak. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Organizations Involved

Timeline

June 2025 June 2026

7 events Latest: Today
Tap a bar to jump to that date
  1. Zydus completes the takeover

    Today Money Moves

    The tender offer closes and Assertio becomes a wholly owned Zydus subsidiary, adding a U.S. oncology drug to its portfolio.

  2. Zydus tops the bid and wins

    Money Moves

    Zydus offers $23.50 a share in all cash. Assertio's board calls it superior and terminates the Garda agreement.

  3. Garda raises its bid

    Money Moves

    Garda lifts its offer to $21.80 a share, a 21% jump from its first price, to keep the deal.

  4. Assertio agrees to sell to Garda

    Money Moves

    Assertio's board agrees to a takeover by Garda Therapeutics, setting off a contest for the company.

  5. Agenus deal clears U.S. security review

    Regulatory

    Zydus completes the Agenus plant purchase after clearance from the Committee on Foreign Investment in the United States.

  6. Zydus targets U.S. biologics plants

    Money Moves

    Zydus announces a plan to buy two California biologics manufacturing sites from Agenus, its first step into U.S. production.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

April 2014

Sun Pharma buys Ranbaxy (2014)

Sun Pharmaceutical agreed to buy troubled rival Ranbaxy in a $4 billion all-stock deal. The merger created India's largest drugmaker and one of the world's biggest generics players.

Then

Sun absorbed Ranbaxy's plants and pipeline despite ongoing U.S. quality problems at some sites.

Now

It cemented a model of Indian firms scaling up through acquisition rather than slow organic growth.

Why this matters now

It set the template Zydus is following: grow abroad by buying, not building.

July 2015

Lupin buys Gavis Pharmaceuticals (2015)

India's Lupin paid about $880 million for U.S. specialty and generics maker Gavis. The deal handed Lupin a New Jersey base and a pipeline of niche American drug filings.

Then

Lupin gained a direct U.S. commercial and manufacturing foothold.

Now

The bet drew mixed results as U.S. generic prices fell, showing the risk in these platform deals.

Why this matters now

It shows both the appeal and the danger of buying a U.S. drug platform for access to the market.

March 2023

Sun Pharma buys Concert Pharmaceuticals (2023)

Sun Pharma acquired U.S. biotech Concert for up to $576 million to gain an experimental hair-loss drug. The deal pushed Sun deeper into branded specialty medicine.

Then

Sun added a late-stage branded asset to its specialty pipeline.

Now

It marked Indian generics leaders moving up into higher-margin branded U.S. products.

Why this matters now

Like Zydus, an Indian generics giant paid up for a branded U.S. specialty drug to escape thin generic margins.

Sources

(8)